Compare INTG & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTG | SCLX |
|---|---|---|
| Founded | 1965 | 2011 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.3M | 59.6M |
| IPO Year | 1995 | N/A |
| Metric | INTG | SCLX |
|---|---|---|
| Price | $37.10 | $7.76 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.4K | ★ 28.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $74,753,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | $84.39 | ★ N/A |
| Revenue Growth | ★ 4.43 | N/A |
| 52 Week Low | $10.37 | $0.18 |
| 52 Week High | $42.50 | $34.27 |
| Indicator | INTG | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 40.52 |
| Support Level | $25.16 | $7.73 |
| Resistance Level | $37.75 | $9.00 |
| Average True Range (ATR) | 1.71 | 0.68 |
| MACD | 0.45 | 0.08 |
| Stochastic Oscillator | 79.74 | 6.25 |
The Intergroup Corp is a company operating in the real estate sector. It was formed to buy, develop, operate, rehabilitate, and dispose of real property of various types and descriptions, as well as to engage in other related business and investment activities. The company operates through three segments: Hotel, Real Estate, and Investment Transactions. The Hotel Operations segment, which generates the majority of the revenue, covers the operation of the Hilton hotel and garage. The Real Estate Operations segment involves the management of multifamily rental properties, while the Investment Transactions segment includes investments of cash in marketable securities and other assets.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.